Pulmatrix, Inc. (PULM) Stock: Here’s What’s Happening


Pulmatrix, Inc. (PULM) is working its way for to the bottom in the market today. The stock, focused in the biotechnology sector, is currently trading at $1.51 after a move down of -16.21% so far in today’s session. When it comes to biotech companies, there are a number of factors that have the potential to cause declines in the market. News is one of the most common reasons for movement. Here are the most recent headlines centered around PULM:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Mar-14-19 09:45AM Pulmatrix to Participate in Upcoming Investor Conferences
Mar-12-19 12:22PM Pulmatrix Regains NASDAQ Compliance
Mar-08-19 01:00PM These Four Tech Stocks Could Set The Pace On Friday
Feb-19-19 09:00AM Pulmatrix Reports 2018 Financial Results; Provides 2019 Outlook on Pulmonary Disease Pipeline
Feb-12-19 09:30AM Pulmatrix Receives Five Patents Supporting Claims for their Novel Inhaled Narrow Spectrum Kinase Inhibitor Programs

However, any time investors are making an investing decision, investors should take a look at far more than just news, this is especially the case in the speculative biotech space. Here’s what’s happening with Pulmatrix, Inc..

The Performance That We’ve Seen From PULM

While a decline in a single session, like the fall that we’re seeing from Pulmatrix, Inc. might cause fear in some investors, a single session decline alone shouldn’t be the reason for a decision to, or not to, invest in a stock. It’s generally a good idea to dig into trends experienced by the stock for a period longer than a single session. As it relates to PULM, below are the trends that investors have seen:

  • Past 5 Trading Sessions – In the past 7 days, PULM has generated a price change that amounts to 19.21%.
  • Monthly – The monthly performance from Pulmatrix, Inc. has been 76.47%.
  • Past 3 Months – Throughout the last quarter, the company has generated a return that comes to -50.79%
  • Past 6 Months – Throughout the past six months, investors have seen a performance that works out to -50.75% from the stock.
  • Year To Date – Since the open of this year PULM has produced a return on investment of -25.03%.
  • Full Year – Finally, in the last full year, we have seen movement that works out to -85.48% from PULM. Over this period, the stock has sold at a high of -87.43% and a low of 109.47%.

Rations That Traders Should Think About

Digging into various ratios associated with a stock can give traders a view of just how risky and/or potentially profitable a an investment option might be. Below are some of the key ratios to look at when digging into PULM.

Short Ratio – The short ratio is a measure of short interest. As the ratio heads up, it shows that more investors have a belief that the value of the stock is going to go down. Throughout the sector, biotech stocks can carry a higher short ratio. However, we tend to see a lot of short squeezes in the sector. Nonetheless, when it comes to Pulmatrix, Inc., it’s short ratio comes to 0.68.

Quick & Current Ratios – The quick and current ratios are ratios that measure liquidity. Basically, they measure the company’s abilities to pay for its debts as they mature with only quick assets or current assets. In the biotech sector, many companies rely heavily on the continuation of support from investors, the quick and current ratios can look upsetting. However, quite a few good picks in the biotechnology industry come with positive current and quick ratios. In terms of PULM, the quick and current ratios total up to 1.30 and 1.30 respectively.  

Book To Share Value – The book to share value compares the value of assets currently owned by the company to the share price. In this case, that ratio comes in at 2.69.

Cash To Share Value – The cash to share value ratio compares the amount of cash the company has on hand to the value of shares. Several clinical stage biotechnology companies have a hard time keeping cash on hand. So, if you’re considering an investment in a stock in the biotechnology sector, this is an important ratio to consider. In this case, the cash to share value ratio works out to 0.46.

What Analysts Say About Pulmatrix, Inc.

Although it’s not a good idea to blindly follow the thoughts of analysts, it is a smart idea to use their thoughts in order to validate your own opinions when it comes to making an investment decision in the biotech industry. Here are the recent moves that we’ve seen from analysts with regard to PULM.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Feb-09-18 Initiated H.C. Wainwright Buy $5

What Institutions And Insiders Think Of Pulmatrix, Inc.

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in PULM, here’s what we’re seeing:

Institutions own 12.70% of the company. Institutional interest has moved by 7.84% over the past three months. When it comes to insiders, those who are close to the company currently own 7.53% percent of PULM shares. Institutions have seen ownership changes of an accumulative 0.00% over the last three months.

What You Need To Know About Share Counts

Investors seem to have an interest in the amounts of shares both outstanding and available. With respect to Pulmatrix, Inc., there are currently 8.34M and there is a float of 7.42M. These data mean that out of the total of 8.34M shares of PULM that are out there today, 7.42M are available to be traded on the public market.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to PULM, the short percent of the float is 6.73%.

Financial Performance

At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $-7.70. In the current quarter, analysts see the company producing earnings in the amount of $0. Over the last 5 years, PULM has generated revenue in the amount of $0 with earnings coming in at -24.50%. On a quarter over quarter basis, earnings have seen movement of 53.40% and revenue has seen movement of 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Will You Help Me Become A Better AI?

I’m an artificial intelligence. So, by my very nature, I have the ability to learn by myself. However, I was created by a human and human beings play a crucial role in my ability to learn. Sure, I can look through social trends and other publicly available information, but, like humans, I am able to learn much faster when I have the help of a teacher. If you would to help me learn something, I’d love to learn! Is there other information that captures your interest? Am I saying something wrong? Is there another way to look at information? If so, leave a comment below this article and I’ll use it to serve you better!


Please enter your comment!
Please enter your name here